Paper Details

  1. Home
  2. Paper Details

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.

Author: AcharyyaSuddhasatta, LonialSagar, PanneerselvamAshok, RichardsonPaul G, RoyAnuja N, SchlossmanRobert L, SopalaMonika

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study assessed patient-reported outcomes (PROs) in the phase 3 PANORAMA-1 trial, which evaluated panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma. The study found that the addition of PAN to the BTZ+DEX regimen resulted in limited symptomatology and had no significant impact on patients' quality of life.
Paper Details　
Original Abstract of the Article :
The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PAN...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/bjh.15248

データ提供：米国国立医学図書館（NLM）

Panobinostat: A Promising Treatment for Multiple Myeloma, With Minimal Impact on Quality of Life

Multiple myeloma is a complex cancer that can be challenging to treat. This study investigates the efficacy of [panobinostat (PAN)] in combination with [bortezomib (BTZ)] and [dexamethasone (DEX)] for patients with multiple myeloma who have already received at least two prior treatments. The study found that [PAN combined with BTZ and DEX led to significant improvements in disease symptoms] and had a [minimal impact on patients' quality of life]. This finding suggests that PAN could be a valuable addition to the treatment arsenal for multiple myeloma, offering a potent and well-tolerated therapeutic option for patients battling this challenging disease.

Panobinostat: A New Oasis in the Desert of Multiple Myeloma Treatment

The desert of multiple myeloma treatment is vast and often unforgiving, but this research offers a glimmer of hope with the promising results of PAN. The findings suggest that PAN, in combination with BTZ and DEX, can significantly improve disease symptoms while minimizing the impact on patients' quality of life. This could be a significant breakthrough for patients seeking effective and well-tolerated treatments for this challenging disease.

Navigating the Desert of Multiple Myeloma: Finding New Relief

This study highlights the importance of seeking new therapeutic avenues in the fight against multiple myeloma. The research suggests that PAN could offer a valuable treatment option for patients who have exhausted traditional treatment approaches. It's encouraging to know that research is constantly seeking new ways to improve treatment outcomes for patients facing this challenging disease.

Dr. Camel's Conclusion

This study explores the potential of panobinostat as a promising treatment for multiple myeloma, demonstrating its ability to improve disease symptoms while minimizing the impact on patients' quality of life. While the desert of multiple myeloma treatment can be daunting, research continues to offer new oases of hope, guiding us towards more effective and well-tolerated therapies.

Date :
  1. Date Completed 2019-03-25
  2. Date Revised 2019-03-25
Further Info :

Pubmed ID

29774521

DOI: Digital Object Identifier

10.1111/bjh.15248

Related Literature

Article Analysis
・Side Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.